First-wave protease inhibitors for hepatitis C genotype 1 treatment: a real-life experience in Brazilian patients
Abstract INTRODUCTION: Licensed for chronic hepatitis C treatment in 2011, the protease inhibitors (PIs) telaprevir (TVR) and boceprevir (BOC), which have high sustained viral responses (SVR), ushered a new era characterized by the development of direct-action drugs against the hepatitis C virus (HC...
Published in: | Revista da Sociedade Brasileira de Medicina Tropical |
---|---|
Main Authors: | , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Sociedade Brasileira de Medicina Tropical (SBMT)
|
Subjects: | |
Online Access: | https://doi.org/10.1590/0037-8682-0153-2017 https://doaj.org/article/fc7765b196994544a338f9435ed7400b |
id |
ftdoajarticles:oai:doaj.org/article:fc7765b196994544a338f9435ed7400b |
---|---|
record_format |
openpolar |
spelling |
ftdoajarticles:oai:doaj.org/article:fc7765b196994544a338f9435ed7400b 2023-05-15T15:10:45+02:00 First-wave protease inhibitors for hepatitis C genotype 1 treatment: a real-life experience in Brazilian patients Silvana Gama Florencio Chachá João Paulo Vilela Rodrigues Roberta Chaves Araújo Leonardo Régis Leira Pereira Márcia Guimarães Villanova Fernanda Fernandes Souza Rodrigo de Carvalho Santana Ana de Lourdes Candolo Martinelli https://doi.org/10.1590/0037-8682-0153-2017 https://doaj.org/article/fc7765b196994544a338f9435ed7400b EN eng Sociedade Brasileira de Medicina Tropical (SBMT) http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822018000200146&lng=en&tlng=en https://doaj.org/toc/1678-9849 1678-9849 doi:10.1590/0037-8682-0153-2017 https://doaj.org/article/fc7765b196994544a338f9435ed7400b Revista da Sociedade Brasileira de Medicina Tropical, Vol 51, Iss 2, Pp 146-154 Hepatitis C vírus Boceprevir Telaprevir Adverse drug reaction Arctic medicine. Tropical medicine RC955-962 article ftdoajarticles https://doi.org/10.1590/0037-8682-0153-2017 2022-12-30T21:39:25Z Abstract INTRODUCTION: Licensed for chronic hepatitis C treatment in 2011, the protease inhibitors (PIs) telaprevir (TVR) and boceprevir (BOC), which have high sustained viral responses (SVR), ushered a new era characterized by the development of direct-action drugs against the hepatitis C virus (HCV). The aim of this study was to analyze the effectiveness and safety of BOC and TVR administered with pegylated interferon and ribavirin and to share the experience of a Brazilian reference center. METHODS: A retrospective descriptive study was conducted in patients with HCV genotype 1 infection who started treatment between July 2013 and December 2015. Data were collected using a computerized system. RESULTS: A total of 115 subjects were included, of which 58 (50.4 %) had liver cirrhosis and 103 (89.6 %) used TVR. The overall SVR rate was 61.7 % (62.1 % for TVR and 58.3 % for BOC). The presence of cirrhosis was associated with a lower SVR rate, whereas patients who relapsed after prior therapy had a greater chance of showing SVR than did non-responders. The incidence of adverse drug reactions (ADRs) was high. Almost all patients (~100 %) presented with hematologic events. Furthermore, treatment had to be discontinued in 15 subjects (13 %) due to severe ADRs. CONCLUSIONS: In conclusion, the SVR rates in our study were lower than those reported in pre-marketing studies but were comparable to real-life data. ADRs, particularly hematological ADRs, were more common compared to those in previous studies and resulted in a high rate of treatment discontinuity. Article in Journal/Newspaper Arctic Directory of Open Access Journals: DOAJ Articles Arctic Revista da Sociedade Brasileira de Medicina Tropical 51 2 146 154 |
institution |
Open Polar |
collection |
Directory of Open Access Journals: DOAJ Articles |
op_collection_id |
ftdoajarticles |
language |
English |
topic |
Hepatitis C vírus Boceprevir Telaprevir Adverse drug reaction Arctic medicine. Tropical medicine RC955-962 |
spellingShingle |
Hepatitis C vírus Boceprevir Telaprevir Adverse drug reaction Arctic medicine. Tropical medicine RC955-962 Silvana Gama Florencio Chachá João Paulo Vilela Rodrigues Roberta Chaves Araújo Leonardo Régis Leira Pereira Márcia Guimarães Villanova Fernanda Fernandes Souza Rodrigo de Carvalho Santana Ana de Lourdes Candolo Martinelli First-wave protease inhibitors for hepatitis C genotype 1 treatment: a real-life experience in Brazilian patients |
topic_facet |
Hepatitis C vírus Boceprevir Telaprevir Adverse drug reaction Arctic medicine. Tropical medicine RC955-962 |
description |
Abstract INTRODUCTION: Licensed for chronic hepatitis C treatment in 2011, the protease inhibitors (PIs) telaprevir (TVR) and boceprevir (BOC), which have high sustained viral responses (SVR), ushered a new era characterized by the development of direct-action drugs against the hepatitis C virus (HCV). The aim of this study was to analyze the effectiveness and safety of BOC and TVR administered with pegylated interferon and ribavirin and to share the experience of a Brazilian reference center. METHODS: A retrospective descriptive study was conducted in patients with HCV genotype 1 infection who started treatment between July 2013 and December 2015. Data were collected using a computerized system. RESULTS: A total of 115 subjects were included, of which 58 (50.4 %) had liver cirrhosis and 103 (89.6 %) used TVR. The overall SVR rate was 61.7 % (62.1 % for TVR and 58.3 % for BOC). The presence of cirrhosis was associated with a lower SVR rate, whereas patients who relapsed after prior therapy had a greater chance of showing SVR than did non-responders. The incidence of adverse drug reactions (ADRs) was high. Almost all patients (~100 %) presented with hematologic events. Furthermore, treatment had to be discontinued in 15 subjects (13 %) due to severe ADRs. CONCLUSIONS: In conclusion, the SVR rates in our study were lower than those reported in pre-marketing studies but were comparable to real-life data. ADRs, particularly hematological ADRs, were more common compared to those in previous studies and resulted in a high rate of treatment discontinuity. |
format |
Article in Journal/Newspaper |
author |
Silvana Gama Florencio Chachá João Paulo Vilela Rodrigues Roberta Chaves Araújo Leonardo Régis Leira Pereira Márcia Guimarães Villanova Fernanda Fernandes Souza Rodrigo de Carvalho Santana Ana de Lourdes Candolo Martinelli |
author_facet |
Silvana Gama Florencio Chachá João Paulo Vilela Rodrigues Roberta Chaves Araújo Leonardo Régis Leira Pereira Márcia Guimarães Villanova Fernanda Fernandes Souza Rodrigo de Carvalho Santana Ana de Lourdes Candolo Martinelli |
author_sort |
Silvana Gama Florencio Chachá |
title |
First-wave protease inhibitors for hepatitis C genotype 1 treatment: a real-life experience in Brazilian patients |
title_short |
First-wave protease inhibitors for hepatitis C genotype 1 treatment: a real-life experience in Brazilian patients |
title_full |
First-wave protease inhibitors for hepatitis C genotype 1 treatment: a real-life experience in Brazilian patients |
title_fullStr |
First-wave protease inhibitors for hepatitis C genotype 1 treatment: a real-life experience in Brazilian patients |
title_full_unstemmed |
First-wave protease inhibitors for hepatitis C genotype 1 treatment: a real-life experience in Brazilian patients |
title_sort |
first-wave protease inhibitors for hepatitis c genotype 1 treatment: a real-life experience in brazilian patients |
publisher |
Sociedade Brasileira de Medicina Tropical (SBMT) |
url |
https://doi.org/10.1590/0037-8682-0153-2017 https://doaj.org/article/fc7765b196994544a338f9435ed7400b |
geographic |
Arctic |
geographic_facet |
Arctic |
genre |
Arctic |
genre_facet |
Arctic |
op_source |
Revista da Sociedade Brasileira de Medicina Tropical, Vol 51, Iss 2, Pp 146-154 |
op_relation |
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822018000200146&lng=en&tlng=en https://doaj.org/toc/1678-9849 1678-9849 doi:10.1590/0037-8682-0153-2017 https://doaj.org/article/fc7765b196994544a338f9435ed7400b |
op_doi |
https://doi.org/10.1590/0037-8682-0153-2017 |
container_title |
Revista da Sociedade Brasileira de Medicina Tropical |
container_volume |
51 |
container_issue |
2 |
container_start_page |
146 |
op_container_end_page |
154 |
_version_ |
1766341714695421952 |